基于网络药理学芩暴红治疗新型冠状病毒感染的可行性分析  

The feasibility of Qinbaohong in the treatment of COVID-19 based on network pharmacology

作　　者：王赛 燕京 王亚玺 周旭东 赵琳 孙洪发 WANG Sai;YAN Jing;WANG Yaxi;ZHOU Xudong;ZHAO Lin;SUN Hongfa

机构地区：[1]河南比福制药股份有限公司研发中心,河南开封475000

出　　处：《中医临床研究》2023年第33期10-16,共7页Clinical Journal Of Chinese Medicine

摘　　要：目的:基于临床病症表现及网络药理学探究芩暴红(黄芩、暴马子皮、满山红)治疗新型冠状病毒感染(Corona Virus Disease 2019,COVID-19)的可行性。方法:首先通过归纳COVID-19各证型的临床表现,总结记载或研究芩暴红功能主治的古籍及现代研究文献,对二者进行对比分析。再通过中药系统药理学数据库与分析平台(TCMSP)、TCM-Taiwan、中国知网、SwissTargetPredictions、Uniprot等数据库收集芩暴红的化学成分及作用靶点,在GeneCards、DisGeNET数据库中得到与COVID-19相关的疾病基因。将药物靶点信息与疾病靶点信息导入DAVID数据库得到共同靶点,进行基因本体论(GO)富集分析与京都基因与基因组百科全书(KEGG)通路富集分析。结果:芩暴红具有清热化痰、止咳平喘的功效,其功能主治与COVID-19的湿热蕴肺证、湿毒郁肺、疫毒夹燥的症状相吻合。亦有研究证明芩暴红中含有的黄芩素、木脂素、槲皮素、山柰酚具有预防COVID-19的可能作用。芩暴红与COVID-19共同靶点98个。关键活性化合物有槲皮素、山柰酚、β-谷甾醇、汉黄芩素、豆甾醇、黄芩素、金合欢素等。主要靶点为丝裂原活化蛋白激酶(Mitogen-Activated Protein Kinase,MAPK)1、MAPK3、热休克蛋白90α家族A类成员1、Jun原癌基因、RELA癌基因、白细胞介素(Interleukin,IL)-6、肿瘤坏死因子(Tumor Necrosis Factor,TNF)、丝氨酸/苏氨酸蛋白激酶1。主要涉及IL-17信号通路、晚期糖基化终末产物-晚期糖基化终末产物受体信号通路、癌症通路、脂质和动脉粥样硬化、TNF信号通路等,涵盖炎症、病毒、代谢等多方面。结论:芩暴红具有通过清热、止咳、化痰、平喘,调节炎症反应、抗病毒、调节糖脂代谢等多方面达到预防和治疗COVID-19的潜力,为临床应用提供理论依据。Objective:To explore the feasibility of Qinbaohong(芩暴红)[Huangqin(Scutellaria baicalensis),Baomazipi(Syringa reticulata var),Manshanhong(Rhododendron dauricum)]in the treatment of COVID-19 based on clinical manifestations and network pharmacology.Methods:Firstly,the clinical manifestations of COVID-19 were summarized,the ancient books and modern research documents on the function of Qinbaohong were summarized or studied,and the two were compared and analyzed.Then,the chemical components and targets of Qinbaohong were collected through TCMSP,TCM-Taiwan,CNKI,SwissTargetPredictions and Uniprot,and the disease genes related to COVID-19 were obtained in GeneCards and DisGeNET databases.The obtained drug target information and disease target information were imported into the DAVID database to obtain common targets,and were used for GO enrichment analysis and KEGG pathway enrichment analysis.Results:Qinbaohong has the effect of clearing heat and resolving phlegm,relieving cough and asthma.Its functions and indications are consistent with the symptoms of damp-heat accumulation of lung syndrome,damp-toxin stagnation of lung,and epidemic toxin blocking dryness of COVID-19.Studies have also proved that baicalein,lignlin,quercetin and kaempferol contained in Qinbahong have a possible role in preventing COVID-19.There are 98 common targets of Qinbaohong and COVID-19.The key active compounds are quercetin,kaempferol,β-sitosterol,wogonin,stigmasterol,baicalein,acacillin and so on.The main targets are MAPK1,MAPK3,HSP90AA1,JUN,RELA,IL-6,TNF,AKT1.It mainly involves IL-17 signaling pathway,AGE-RAGE signaling pathway,cancer pathway,lipid and atherosclerosis,TNF signaling pathway,etc.,covering inflammation,virus,metabolism and other aspects.Conclusion:Qinbaohong has the potential to prevent and treat COVID-19 by clearing heat,relieving cough,resolving phlegm,relieving asthma,regulating inflammatory response,antiviral,and regulating glucose and lipid metabolism and other aspects,and provides a theoretical basis for clinical app

关 键 词：新型冠状病毒感染 芩暴红 网络药理学 黄芩 暴马子皮 

分 类 号：R256.1[医药卫生—中医内科学]